MedTrace Logo

Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents

NCT02236273 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 956

Last updated 2025-07-29

Study results available
· View outcomes & findings →

Summary

Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored approach. The trans-theoretical model of behavior change supports tailoring interventions to an individual's stage of decision-making. Human papillomavirus (HPV) is the most prevalent sexually transmitted virus in the U.S. and can lead to genital warts, and cervical, anal and penile cancer. The three-dose vaccine is 90-100% efficacious. Minorities are at greatest risk for such cancers but have low HPV vaccine completion rates. Limited health literacy regarding the vaccine can affect series completion. The investigators will compare the effects of enhancing text message vaccination reminders with interactive, vaccine health literacy-promoting information tailored to vaccine decision making-stage on HPV vaccine series completion. The effects of these messages represent a new paradigm in interactive health communications.

Conditions

  • Human Papillomavirus

Interventions

BEHAVIORAL

Conventional text message reminder

Receipt of conventional text message notifying when due for next dose

BEHAVIORAL

Enhanced text message reminders

Receipt of enhanced text messages notifying when due for next dose coupled with educational information

Sponsors & Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)

    collaborator FED

  • Columbia University

    lead OTHER

Principal Investigators

  • Melissa S Stockwell, MD MPH · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02236273 on ClinicalTrials.gov